Abstract
This study was designed to determine the relationship between plasma asymmetric dimethylarginine (ADMA) and the development of carotid atherosclerosis. Cross-sectional studies have revealed that plasma ADMA concentration is correlated with the intima-media thickness (IMT) of the carotid artery, but no prospective studies have appeared. Therefore we prospectively investigated whether or not plasma ADMA level can predict IMT progression. In a community-based cohort, we enrolled 712 subjects who were over 40 years old and who had no apparent cardiovascular diseases according to high-resolution carotid ultrasonography. Blood chemistries including ADMA were measured at baseline. In 575 subjects, IMT was re-measured 6 years later. The value of baseline ADMA for predicting IMT changes was investigated by multivariable analysis. At baseline, there was a significant (β=0.321; p<0.001) relationship between IMT and ADMA levels. Multiple linear regression analysis revealed that baseline ADMA (β=0.241; p<0.01) was the only predictor of IMT progression after adjustments for age, sex, baseline IMT, and four major risk factors (hypertension, hypercholesterolemia, diabetes mellitus, and smoking) plus hyperuricacidemia. Plasma ADMA was a predictor of carotid IMT progression.
Similar content being viewed by others
Article PDF
References
Nakashima A, Matsuoka H, Yasukawa H, et al: Renal denervation prevents intraglomerular platelet aggregation and glomerular injury induced by chronic inhibition of nitric oxide synthesis. Nephron 1996; 73: 34–40.
Ikeda H, Takajo Y, Murohara T, et al: Platelet-derived nitric oxide and coronary risk factors. Hypertension 2000; 35: 904–907.
Katoh A, Ikeda H, Takajo Y, et al: Coexistence of impairment of endothelium-derived nitric oxide and platelet-derived nitric oxide in patients with coronary risk factors. Circ J 2002; 66: 837–840.
Cooke JP, Dzau VJ : Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997; 48: 489–509.
Ware JA, Heistad DD : Platelet-endothelium interactions. N Engl J Med 1993; 328: 628–635.
Moncada S, Higgs A : The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002–2012.
Matsuoka H, Itoh S, Kimoto M, et al: Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension 1997; 29: 242–247.
Miyazaki H, Matsuoka H, Cooke JP, et al: Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141–1146.
Cooke JP : Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2032–2037.
Achan V, Broadhead M, Malaki M, et al: Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455–1459.
Kielstein JT, Bode-Boger SM, Frolich JC, Ritz E, Haller H, Fliser D : Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation 2003; 107: 1891–1895.
Surdacki A, Nowicki M, Sandmann J, et al: Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652–658.
Vallance P, Leone A, Calver A, Collier J, Moncada S : Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572–575.
Lundman P, Eriksson MJ, Stuhlinger M, Cooke JP, Hamsten A, Tornvall P : Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001; 38: 111–116.
Zoccali C, Bode-Boger SM, Mallamaci F, et al: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113–2117.
Valkonen VP, Pälvä H, Salonen JT, et al: Risk of acute coronary events and serum concentration of asymmetrical dimethylargine. Risk of acute coronary events and serum concentration of asymmetrical dimethylargine. Lancet 2001; 358: 2127–2128.
Krempl TK, Maas R, Sydow K, Meinertz T, Böger RH, Kähler J : Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J 2005; 26: 1846–1851.
Furuki K, Adachi H, Matsuoka H, et al: Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery—an epidemiological study—. Atherosclerosis 2007; 191: 206–210.
Nanayakkara PW, Teerlink T, Stehouwer CD, et al: Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int 2005; 68: 2230–2236.
Hino A, Adachi H, Toyomasu K, et al: Very long chain N-3 fatty acids intake and carotid atherosclerosis—an epidemiological study evaluated by ultrasonography—. Atherosclerosis 2004; 176: 145–149.
SAS Institute : SAS/STAT Software: Changes and Enhancements through Release 6.12. Cary, SAS Institute Inc, 1997.
O’Leary DH, Polak JF, Kbonmal RA, Manolio TA, Burke GL, Wolfson SK, for the Cardiovascular Health Study Collaborative Research Group: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14–22.
Zoccali C, Benedetto FA, Maas R, et al: Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002; 13: 490–496.
Boger RH, Zoccali C : ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atherosclerosis 2003; 4: 23–28.
Zoccali C : Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens 2006; 24: 611–619.
Pitt B, Byington RP, Furberg CD, et al: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503–1510.
Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF : Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blind trial. Lancet 2001; 357: 577–581.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Furuki, K., Adachi, H., Enomoto, M. et al. Plasma Level of Asymmetric Dimethylarginine (ADMA) as a Predictor of Carotid Intima-Media Thickness Progression: Six-Year Prospective Study Using Carotid Ultrasonography. Hypertens Res 31, 1185–1189 (2008). https://doi.org/10.1291/hypres.31.1185
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.1185
Keywords
This article is cited by
-
The interplay between exposure to PAHs and MTHFR C677T polymorphism on cardiovascular risk biomarkers in Mexican women
Environmental Science and Pollution Research (2022)
-
Asymmetric dimethylarginine and l-homoarginine prospectively relate to carotid wall thickness in a South African cohort
Amino Acids (2020)
-
Nitric oxide synthesis capacity, ambulatory blood pressure and end organ damage in a black and white population: the SABPA study
Amino Acids (2016)
-
Role of asymmetric dimethylarginine in the progression of carotid atherosclerosis in renal transplant patients
International Urology and Nephrology (2013)
-
Asymmetric dimethylarginine and carotid atherosclerosis in Type 2 diabetes mellitus
Journal of Endocrinological Investigation (2012)